Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)

@inproceedings{Nash2018EfficacyAS,
  title={Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)},
  author={Peter Nash and Philip J Mease and Iain B McInnes and Proton Rahman and Christopher T Ritchlin and Ricardo Blanco and Eva Dokoupilov{\'a} and Mats Erik Andersson and Radhika Kajekar and Shephard Mpofu and Luminita Pricop},
  booktitle={Arthritis Research & Therapy},
  year={2018}
}
BackgroundThe study aimed to assess 52-week efficacy and safety of secukinumab self-administration by autoinjector in patients with active psoriatic arthritis (PsA) in the FUTURE 3 study (ClinicalTrials.gov NCT01989468).MethodsPatients (≥ 18 years of age; N = 414) with active PsA were randomized 1:1:1 to subcutaneous (s.c.) secukinumab 300 mg, 150 mg, or placebo at baseline, weeks 1, 2, 3, and 4, and every 4 weeks thereafter. Per clinical response, placebo-treated patients were re-randomized to… CONTINUE READING

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 25 REFERENCES

Secukinumab for long-term treatment of psoriatic arthritis: 2-year follow-up from a phase 3, randomized, double-blind, placebo-controlled study

  • A Kavanaugh, PJ Mease, +3 authors S Hall
  • Arthritis Care Res (Hoboken)
  • 2017
VIEW 1 EXCERPT